Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabidiol + Hemp Extract is an investigational herbal preparation developed by Chaopraya Abhaibhubejhr Hospital in Thailand. The product is a combination of purified cannabidiol (CBD) and a plant-derived hemp extract, sourced from the Cannabis plant. It is being explored for use in neurological and seizure-related conditions, including Parkinson's disease and epilepsy, as part of the hospital's traditional Thai medicine research and development pipeline. The drug acts primarily by modulating the endocannabinoid system through interactions with cannabinoid receptors (CB1 and CB2), as well as non-cannabinoid targets such as TRPV1 and serotonin receptors. It is currently listed as a hospital-based investigational product without formal Phase 1/2/3 clinical trial designations or regulatory approval status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabidiol + hemp extract.